The shares of Common Stock reported herein were acquired solely for investment purposes. None of the Reporting Persons have any present plans or proposals that relate to or would result in any change in the business, policies, management, structure or capitalization of the Issuer. The Reporting Persons reserve the right to acquire, or dispose of, additional securities of the Issuer in the ordinary course of their business, to the extent deemed advisable in light of their general investment and trading policies, market conditions or other factors. The Reporting Persons may engage in discussions from time to time with other stockholders of the Issuer regarding the acquisition by the Reporting Persons of others of shares of the Issuer's Common Stock held by such stockholders. Additionally, the Reporting Persons may acquire additional securities through open market transactions, privately negotiated transactions or other methods. In connection with the foregoing, and as may be appropriate from time to time, each of the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to the Reporting Persons investment in the Issuer, including, without limitation: (a) the acquisition or disposition of Common Stock, including through derivative transactions which may include security-based swaps and short sales; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) other material changes in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation or bylaws or other actions that may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12 of the Exchange Act; or (j) any action similar to those enumerated above. Except as described in Item 6 and this Item 4, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of this paragraph. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments. Isaac Manke, an affiliate of the Reporting Persons, serves on the board of directors of the Issuer. The Reporting Persons have established policies and procedures to ensure that (i) material nonpublic information concerning the Issuer is not obtained by the Reporting Persons from Mr. Manke and (ii) Mr. Manke does not participate in or make investment decisions on behalf of the Reporting Persons with respect to the Reporting Persons investment in the Issuer's Common Stock. October 2024 Merger On October 4, 2024, the Issuer (f/k/a Reneo Pharmaceuticals, Inc.) consummated a merger (the "Merger") pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024, by and among the Issuer, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Issuer, Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Issuer, and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). Pursuant to the Merger, the Issuer changed its name to "OnKure Therapeutics, Inc.", and Radiate Merger Sub I, Inc. merged with and into Legacy OnKure, with Legacy OnKure as the surviving company in the Merger and, after giving effect to such Merger, Legacy OnKure became a wholly owned subsidiary of the Issuer. In connection with the Merger, the securities of Legacy OnKure previously held by Acorn were converted into the right to receive 1,439,674 shares of the Issuer's Common Stock. May 2025 Purchase On May 15, 2025, Acorn and Acorn 2 acquired 270,270 shares and 1,129,730 shares, respectively, of the Issuer's Common Stock in an open market block purchase. The shares were acquired at a price of $8.15 per share, for an aggregate consideration of $11,410,000, using funds from working capital.